美康生物: 第五届监事会第十三次会议决议公告

Core Viewpoint - The company has approved the use of idle raised funds for cash management, which is expected to enhance the efficiency of fund utilization and provide better returns for shareholders without affecting the company's normal operations or main business development [1][2]. Group 1 - The fifth session of the company's supervisory board was held on May 30, 2025, with all legal requirements met for the meeting [1]. - The supervisory board unanimously approved the proposal to use up to RMB 100 million of temporarily idle raised funds for cash management [1]. - The decision is in compliance with relevant regulations and will not harm the interests of the company or its shareholders, particularly minority shareholders [1][2]. Group 2 - The voting results for the proposal were 3 votes in favor, 0 votes against, and 0 abstentions [2]. - The company will ensure that the use of these funds does not impact the normal turnover of funds or the implementation of investment projects [1]. - The decision aligns with various regulatory guidelines and the company's articles of association [1].